• LAST PRICE
    3.5700
  • TODAY'S CHANGE (%)
    Trending Up0.0900 (2.5862%)
  • Bid / Lots
    3.5300/ 1
  • Ask / Lots
    3.6900/ 1
  • Open / Previous Close
    3.5500 / 3.4800
  • Day Range
    Low 3.5200
    High 3.6300
  • 52 Week Range
    Low 1.6701
    High 4.7400
  • Volume
    613,584
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.48
TimeVolumeCBAY
09:32 ET33503.57
09:34 ET24343.55
09:36 ET2683.54
09:38 ET4003.54
09:41 ET15443.5905
09:43 ET2613.59
09:48 ET12003.585
09:52 ET1003.58
09:54 ET10003.58
09:57 ET6003.565
09:59 ET23453.555
10:01 ET27003.58
10:03 ET138283.61
10:06 ET36973.61
10:08 ET10003.59
10:10 ET7323.62
10:12 ET6003.61
10:14 ET3003.6
10:19 ET4003.58
10:21 ET2003.595
10:24 ET3003.6
10:26 ET12743.62
10:28 ET5213.62
10:33 ET12863.63
10:35 ET9483.63
10:37 ET12003.605
10:39 ET4003.6
10:48 ET3253.605
10:53 ET3003.605
10:55 ET1003.61
10:57 ET1003.6
11:02 ET555893.61
11:04 ET146283.6
11:06 ET179993.6
11:08 ET2003.585
11:09 ET27663.58
11:11 ET676723.59
11:13 ET25003.6
11:15 ET81993.6
11:18 ET4333.585
11:20 ET1003.585
11:22 ET21003.585
11:26 ET108603.61
11:27 ET6663.5988
11:29 ET1003.59
11:31 ET10483.59
11:33 ET13003.58
11:36 ET1003.59
11:38 ET10003.5806
11:42 ET8813.585
11:44 ET1003.59
11:45 ET1003.58
11:51 ET30003.61
11:54 ET11003.615
11:56 ET8003.62
12:03 ET3103.62
12:05 ET1913.6106
12:07 ET78953.59
12:09 ET5663.59
12:12 ET2003.595
12:14 ET1003.6
12:16 ET7483.62
12:18 ET15943.62
12:20 ET37483.61
12:21 ET6273.61
12:23 ET9003.59
12:25 ET1003.59
12:32 ET45233.59
12:36 ET17003.59
12:43 ET6323.61
12:45 ET16723.605
12:48 ET19163.61
12:50 ET4003.61
12:52 ET1003.61
12:54 ET3003.605
12:56 ET2003.61
12:59 ET1003.61
01:01 ET33753.61
01:03 ET6003.61
01:06 ET1003.605
01:08 ET4303.61
01:10 ET99803.611
01:12 ET6953.6047
01:14 ET753353.61
01:15 ET19003.61
01:17 ET5003.6
01:19 ET31763.61
01:21 ET40123.61
01:24 ET22423.6
01:26 ET1003.6
01:28 ET169703.5809
01:30 ET10213.5901
01:33 ET10003.6
01:35 ET1003.6
01:37 ET2003.6
01:39 ET27003.59
01:42 ET18663.59
01:44 ET8673.585
01:46 ET3003.5894
01:48 ET2253.58
01:57 ET56983.57
02:00 ET1003.565
02:04 ET25373.57
02:08 ET1003.565
02:13 ET28693.57
02:18 ET9503.565
02:22 ET1003.565
02:24 ET15003.575
02:27 ET1003.57
02:29 ET5003.57
02:31 ET34513.56
02:33 ET49673.55
02:36 ET42843.561
02:38 ET44413.56
02:42 ET17003.55
02:54 ET1003.55
03:00 ET1003.55
03:02 ET143743.565
03:03 ET57153.56
03:05 ET18003.56
03:07 ET8003.569
03:09 ET37953.56
03:14 ET44803.565
03:18 ET1003.5647
03:20 ET1003.57
03:21 ET3003.56
03:23 ET1003.57
03:25 ET56723.57
03:27 ET64803.6
03:30 ET76213.59
03:32 ET120923.61
03:34 ET26833.59
03:36 ET43703.6
03:38 ET1003.6
03:39 ET101973.6
03:41 ET62773.6
03:43 ET10003.6
03:45 ET14773.6
03:48 ET16263.6
03:50 ET63273.6
03:52 ET60803.59
03:54 ET31563.5804
03:56 ET19993.57
03:57 ET33103.585
03:59 ET75143.57
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCBAY
Cymabay Therapeutics Inc
293.0M
-2.8x
---
United StatesANNX
Annexon Inc
287.1M
-1.6x
---
United StatesGBIO
Generation Bio Co
276.2M
-2.3x
---
United StatesAADI
Aadi Bioscience Inc
262.7M
-1.2x
---
United StatesBCAB
Bioatla Inc
274.2M
-2.9x
---
United StatesABSI
Absci Corp
273.9M
-2.6x
---
As of 2022-09-28

Company Information

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. It is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

Contact Information

Headquarters
SUITE 130, 7999 GATEWAY BLVDNEWARK, CA, United States 94560
Phone
510-293-8800
Fax
510-293-9090

Executives

Independent Chairman of the Board
Robert Wills
President, Chief Executive Officer, Director
Sujal Shah
Senior Vice President, Chief Scientific Officer
Charles McWherter
Chief Compliance Officer, General Counsel, Corporate Secretary
Paul Quinlan
Vice President - Finance
Daniel Menold

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$293.0M
Revenue (TTM)
$0.00
Shares Outstanding
84.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.59
EPS
$-1.30
Book Value
$1.57
P/E Ratio
-2.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.